ACCOMPLISHMENTS
A4M serves as an advocate for the new clinical specialty of anti-aging medical science and acts as a conduit to physicians, scientists, and the educated public who wish to benefit from the almost daily breakthroughs in biotechnology which promise both a greater quality as well as quantity of life. The A4M is the:
•First to create the anti-aging medical movement.
•Founder of the world’s fastest-growing medical specialty.
•Leading provider of university academic co-sponsored medical education in the field.
•Recognized leadership for a $295 billion marketplace
Nearly 3 decades ago, the founding members of the A4M predicted the shift in the global demographics towards a worldwide greying trend, and the organization forged a model for clinical healthcare to advance preventive healthcare by applying cutting-edge diagnostic and therapeutic technologies. An array of life-enhancing, life-extending achievements for human longevity has since resulted. World-renowned speakers at the A4M’s Annual Congresses on Anti-Aging Medicine have debuted breakthrough findings that include:
Table 2. Preventative Medical Breakthroughs Based in Anti-Aging Science (partial list)
| 2015: | |
| Microbiome in brain health [Perlmutter] | |
| Cardiac-neurological-immune connection [Houston] | |
| 2010: | |
| Concussion in Neurodegenerative Disease [Maroon] | |
| 2007: | |
| Traumatic Brain Injury (TBI) & hormone dysregulation [Gordon] | |
| 2006: | |
| Phytonutrients for prevention of atherosclerosis [Siegel] | |
| 2005: | |
| Inflammation in neurodegenerative disorders [Perlmutter] | |
| Fatty acids for cardiovascular health [Rothenberg] | |
| 2003: | |
| Inflammation in cardiovascular disease [Sinatra] | |
| Vaccine for Alzheimer’s Disease [Da Silva] | |
| 1999: | |
| Insulin in aging [Sears] | |
| Calcium for the prevention and treatment of osteoporosis [Fujita] | |
| Thyroid dysfunction in aging [Rouzier; Hertoghe] | |
| 1998: | |
| Natural compounds for cancer prevention & therapy [Holt; Lane] | |
| CoEnzyme Q10 & cardiovascular disease [Sinatra] | |
| Noninvasive scans for brain assessment [Braverman] | |
| 1997: | |
| Homocysteine as a marker for heart disease [Fox] | |
| Cerebrovascular assessment & treatment [Braverman; Bodo] | |
| 1996: | |
| Importance of growth hormone in adulthood [Hertoghe] | |
| DHEA [Regelson] | |
| Molecular nanotechnology in medicine [Merkle] | |
| 1995: | |
| Melatonin as cancer-fighting compound [Lissoni] | |
| Nutritional therapies for aging-related memory decline [Khalsa; Kidd] | |
| Reversal of skin aging with non-/minimally-invasive techniques [Giacomoni] |
ADOPTION
Today, multinational companies are pouring billions of dollars into anti-aging medical technologies. In particular, Silicon Valley has engaged significant resources: each of these megacorporations proudly equates themselves with “anti-aging.” As such, the phrase “anti-aging” is now poised for transformation from a disparaged term to one of prestige and dominance.
Google backs privately held 23andMe, which offers a DNA test for consumers who can secure genetic reports and ancestry-related data. In 2013 by Google’s CEO and co-founder, Larry Page – 40 years old at the time, founded Calico (California Life Company) with $1 billion in start-up funding. Describing its goal as “focusing on the challenge of aging and associated diseases.” Page has observed that: “With some longer term, moonshot thinking around healthcare and biotechnology, I believe we can improve millions of lives.”1 Calico is headed by Art Levinson, former CEO of Genetech, a highly successful biotech company specializing in cancer therapies.
In mid-2014, Calico forged a 10-year R&D collaboration deal with AbbVie Inc., a major US drugmaker (notably, Humira®, a rheumatoid arthritis biologic).2 Each company is reported to invest an initial $250 million, with a possible additional $500 million in the future. Using this funding, Calico will use its scientific expertise to establish